These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15109669)

  • 1. Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.
    Sham HL; Betebenner DA; Rosenbrook W; Herrin T; Saldivar A; Vasavanonda S; Plattner JJ; Norbeck DW
    Bioorg Med Chem Lett; 2004 May; 14(10):2643-5. PubMed ID: 15109669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.
    Sham HL; Zhao C; Li L; Betebenner DA; Saldivar A; Vasavanonda S; Kempf DJ; Plattner JJ; Norbeck DW
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3101-3. PubMed ID: 12372511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).
    Sham HL; Betebenner DA; Chen X; Saldivar A; Vasavanonda S; Kempf DJ; Plattner JJ; Norbeck DW
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1185-7. PubMed ID: 11934584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
    Flosi WJ; DeGoey DA; Grampovnik DJ; Chen HJ; Klein LL; Dekhtyar T; Masse S; Marsh KC; Mo HM; Kempf D
    Bioorg Med Chem; 2006 Oct; 14(19):6695-712. PubMed ID: 16828558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
    Raghavan S; Lu Z; Beeson T; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Gabryelski L; Emini E; Tata JR
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5432-6. PubMed ID: 17692518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
    J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
    Zhao C; Sham HL; Sun M; Stoll VS; Stewart KD; Lin S; Mo H; Vasavanonda S; Saldivar A; Park C; McDonald EJ; Marsh KC; Klein LL; Kempf DJ; Norbeck DW
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5499-503. PubMed ID: 16203141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).
    Sham HL; Betebenner DA; Herrin T; Kumar G; Saldivar A; Vasavanonda S; Molla A; Kempf DJ; Plattner JJ; Norbeck DW
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1351-3. PubMed ID: 11378352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
    Wilkerson WW; Dax S; Cheatham WW
    J Med Chem; 1997 Dec; 40(25):4079-88. PubMed ID: 9406598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of novel cyclic urea based HIV-1 protease inhibitors.
    Nugiel DA; Reese K
    Drug Des Discov; 1995 Nov; 13(2):83-7. PubMed ID: 8872453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
    Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
    Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
    Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
    J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.